Invesaro

Stocks Health care CRL

NYSE · Health care

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. brought in $4B of revenue over the twelve months to June 27, 2026, down 0.7% from a year earlier. It posted a net loss of $238.5M. Operating cash flow minus capital spending left $518.5M of free cash flow in fiscal 2025. At June 27, 2026 it held $192M in cash against $5.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price
$292.84
-0.54% on the day · September 25, 2026
52-week range $145.47 to $303.31
Market cap
$14B
Revenue (last 12 months)
$4B
-0.7% year on year
Net margin
-6.0%

What Charles River Laboratories International, Inc. does

Charles River Laboratories International, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NYSE under the ticker CRL.

Revenue and profit by year

Revenue
FY18: $2.3B $2.3B FY18FY19: $2.6B $2.6B FY19FY20: $2.9B $2.9B FY20FY21: $3.5B $3.5B FY21FY22: $4B $4B FY22FY23: $4.1B $4.1B FY23FY24: $4B $4B FY24FY25: $4B $4B FY25
Net income
FY18: $226.4M $226.4M FY18FY19: $252M $252M FY19FY20: $364.3M $364.3M FY20FY21: $391M $391M FY21FY22: $486.2M $486.2M FY22FY23: $474.6M $474.6M FY23FY24: $22.2M $22.2M FY24FY25: -$144.3M -$144.3M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$4B$25.2M-$144.3M-$2.91$518.5M
2024$4B$227.3M$22.2M$0.20$501.6M
2023$4.1B$617.3M$474.6M$9.22$365.4M
2022$4B$651M$486.2M$9.48$294.9M
2021$3.5B$589.9M$391M$7.60$532M
2020$2.9B$432.7M$364.3M$7.20$380M

Latest SEC filings

What Charles River Laboratories International, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 24, 2026
  2. September 8, 2026
  3. August 6, 2026
  4. August 5, 2026
    Quarterly report 10-Q · period to June 27, 2026
  5. August 5, 2026
  6. May 11, 2026
  7. May 11, 2026
  8. May 7, 2026
  9. May 7, 2026
    Quarterly report 10-Q · period to March 28, 2026
  10. May 7, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 27, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CRL

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NYSE under the ticker CRL.

Is Charles River Laboratories International, Inc. profitable?

No. Over the twelve months to June 27, 2026 it reported a net loss of $238.5M on revenue of $4B.

How much revenue does Charles River Laboratories International, Inc. make?

Over the twelve months to June 27, 2026 Charles River Laboratories International, Inc. reported revenue of $4B. That is 0.7% less than a year earlier.

When did Charles River Laboratories International, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 27, 2026. Its newest filing of any kind is the investor disclosure from September 24, 2026.

Similar companies

Follow CRL

Get an email when Charles River Laboratories International, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CRL: get an email when it files

Where the numbers come from

Financial figures are the values Charles River Laboratories International, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.